Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Fenebrutinib targets cells in the immune system known as B cells and microglia
Subscribe To Our Newsletter & Stay Updated
